Category: W.L. Gore & AssociatesSyndicate content

Gore's Viabahn stent graft bests angioplasty, study finds

February 20, 2014 by Arezu Sarvestani

W.L. Gore's newly approved drug-coated Viabahn stent graft beat the current standard of care in treating patients with stenoses or thrombotic occlusions, according to the REVISE clinical study findings.

Gore's Viabahn stent graft bests angioplasty, study finds

Arizona medical device maker W.L. Gore & Assoc. teased positive results from its REVISE clinical trial, promising to release additional findings during the American Society of Diagnostic & Interventional Nephrology meeting in Phoenix this week.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Legal win, buyouts boost Bard's bottom line

February 3, 2014 by Brian Johnson

C.R. Bard's 4th-quarter bottom line gets a significant boost from a nearly $900 million legal payment from rival W.L. Gore and the more than $200 million gain from selling its electrophysiology business to Boston Scientific.

A nearly $900 million award from W.L. Gore boosted C.R. Bard's bottom line in Q4 as sales inch up 3% in 2013: Officials announce $500 million share buyback plan.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Gore opens U.S. endoprosthesis trial

January 30, 2014 by Chris Walker

W.L. Gore enrolls its 1st patient in the Gore TAG thoracic branch endoprosthesis LSA feasibility study in the U.S.

Gore opens endoprosthesis trial

W.L. Gore & Associates enrolled the 1st patient in its U.S. Gore TAG thoracic branch endoprosthesis LSA feasibility study in hopes of landing FDA approval for treatment of thoracic aortic aneurysms in the left subclavian artery.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Gore appeals $860M loss to Bard

December 12, 2013 by Brad Perriello

W.L. Gore & Assoc. appeals its $860 million patent infringement loss to C.R. Bard over stent graft technology.

Gore appeals $860M loss to Bard

C.R. Bard (NYSE:BCR) had no standing to bring the patent infringement lawsuit that won it a nearly $860 million verdict against W.L. Gore & Assoc., Gore argued in its appeal yesterday.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Gore lands FDA expanded approval for Viabahn endoprosthesis

December 11, 2013 by Arezu Sarvestani

W.L. Gore touts expanded approval to market its Viabahn endoprosthesis to treat stenosis and thrombosis in synthetic vascular access grafts.

Gore lands FDA expanded approval for Viabahn endoprosthesis

W.L. Gore & Associates today touted expanded FDA approval for its Viabahn endoprosthesis, now indicated for treatment of stenosis and thrombotic occlusions related to synthetic vascular access grafts.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Gore wins Japanese approval for Excluder endoprosthesis

December 6, 2013 by Chris Walker

W.L. Gore & Associates lands Japanese approval for its Excluder AAA endoprosthesis with the C3 delivery system.

Gore wins Japanese approval for endoprosthesis delivery system

W.L. Gore & Associates said it won Shonin approval from the Japanese Ministry of Health, Labor & Welfare to market its Excluder AAA endoprosthesis with C3 delivery system for treatment of abdominal aortic aneurysms.

Gore launches Excluder study of iliac branch endoprosthesis

November 15, 2013 by Chris Walker

Gore's enrolls the 1st patient in a clinical trial of its Excluder iliac branch devices in treatment of patients with common iliac artery aneurysms.

Gore launches Excluder study

W.L. Gore & Associates this week enrolled its 1st patient in a study of its Excluder iliac branch devices, evaluating the implants in treatment of common iliac artery aneurysms or aorto-iliac aneurysms.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp